Automatic and accurate auxiliary detection of lung cancer pathological classification based on novel lightweight deep...

Lung cancer is one of the major cancers worldwide, and rapid, accurate diagnosis is crucial for subsequent treatment and management. Currently, pathological subtype detection requires clinical experts to invest significant time and effort, making the development of automatic, efficient detection models essential.

This study developed a novel deep learning model named BreezeNet for the recognition of lung adenocarcinoma, lung squamous cell carcinoma, and benign lung tissue. BreezeNet is a lightweight deep learning framework specifically designed for precise and automated diagnosis of lung adenocarcinoma, lung squamous cell carcinoma, and benign lung tissue. Compared with current mainstream deep learning models such as VGG, GoogleNet, and MobileNet, BreezeNet demonstrated superior performance in key metrics such as precision and accuracy.

In our study, we developed a lightweight deep learning model named BreezeNet for the automatic classification of lung cancer cells. The experimental results show that BreezeNet performs excellently across various metrics, particularly in terms of the number of parameters. Specifically, BreezeNet achieved a precision of 0.9749, a recall of 0.9742, an F1-score of 0.9742, and an accuracy of 0.9789, which are slightly better than traditional deep learning models such as AlexNet, VGG, GoogleNet, ResNet, and MobileNet. However, the most significant advantage of BreezeNet lies in its parameter count, which is only 1,256,679, far lower than AlexNet's 14,587,587 and ResNet's 23,514,179. This means that our model is not only competitive in terms of performance but also significantly reduces the computational resource requirements, greatly enhancing the model's lightweight nature and deployment efficiency.

Compared with traditional deep learning models such as AlexNet, VGG, and ResNet, BreezeNet achieves slightly better performance across all key metrics, with up to 1.6% higher accuracy, 1.76% higher F1-score, and over 18× fewer parameters, highlighting its superior lightweight design and diagnostic effectiveness. Our developed deep learning model can efficiently perform automated subtyping of lung cancer cells, providing accurate diagnostic recommendations for doctors. This will help improve the efficiency of lung cancer diagnosis, thereby enhancing patient survival rates.